The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphoma
Vincenzo Perriello, MD, PhD, University of Perugia, Perugia, Italy, shares some insights into the promise of dual-targeting CAR-T therapy for the treatment of Hodgkin lymphoma (HL), and highlights a novel CD30/PDL1 construct being explored. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Classic Hodgkin lymphoma is the most common cancer among teenagers. And despite the high cure rate with first-line and salvage therapy, 15 to 20% of patients do not achieve a long-term disease-free survival. So, we need new alternative therapies in this setting and CAR-T cell therapy could be a promising approach.
We decided to develop a new target strategy by anti-CD30 CAR-T cell, coupled with a PD-L1 costimulatory receptor to overcome the resistance of the tumor microenvironment...
Classic Hodgkin lymphoma is the most common cancer among teenagers. And despite the high cure rate with first-line and salvage therapy, 15 to 20% of patients do not achieve a long-term disease-free survival. So, we need new alternative therapies in this setting and CAR-T cell therapy could be a promising approach.
We decided to develop a new target strategy by anti-CD30 CAR-T cell, coupled with a PD-L1 costimulatory receptor to overcome the resistance of the tumor microenvironment. CD30 CAR-T cells have been explored by several CAR constructs, but despite the initial overall response rate, most of these CAR-T cells do not persist in time.
The longer follow-up of these trials showed that the progression-free survival is quite low. So we need to boost the T-cell activation on the tumor microenvironment to let persist CAR-T cells more time in the tumor microenvironment to achieve a more deep response.
Read more...
